The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and ...

Pfizer Inc. (NYSE:PFE) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not ...

The drug-pricing agreement Pfizer struck with the Trump administration in September could generate up to $280 million in annual savings for state Medicaid programs, according to an analysis published ...

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion and ...

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

The approval covers all 27 EU member states, Liechtenstein, Norway, and Iceland.

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Those eager to discredit Pfizer's mRNA vaccine, which is safe and effective, exploited the cruise ship outbreak.